Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Markman

Showing results (1-10 of 545) with videos related to

Pageof 55
Sort By:
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1990
Supportive careM Markman
Gynecologic Oncology|June 13, 1998
"Recurrence within 6 months of platinum therapy": an adequate definition of "platinum-refractory" ovarian cancer?M Markman
Cleveland Clinic Journal of Medicine|May 23, 1998
The high cost of terminal care: balancing conflicting goalsM Markman
Seminars in Oncology|August 1, 1989
Intraperitoneal cisplatin chemotherapy in the management of ovarian carcinomaM Markman
Cancer Investigation|January 1, 1987
Clinical cancer research, DNR orders, and medical economics: a complex interrelationshipM Markman
The American Journal of the Medical Sciences|March 1, 1986
Cytotoxic intracavitary chemotherapyM Markman
Journal of Cancer Research and Clinical Oncology|January 1, 1995
Thirty-first annual meeting of the American Society of Clinical Oncology. Los Angeles, California, 20-23 May 1995M Markman
Journal of Cancer Research and Clinical Oncology|January 1, 1993
The role of platinum dose intensity in the management of ovarian cancerM Markman
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Salvage intraperitoneal chemotherapy for ovarian cancer: a possible role for mitoxantrone?M Markman
Journal of Cancer Research and Clinical Oncology|January 1, 1994
Pharmaceutical advertising and the cost of medical careM Markman
Pageof 55

Showing results (1-10 of 545) with videos related to

Sort By:
Pageof 55
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1990
Supportive careM Markman
Gynecologic Oncology|June 13, 1998
"Recurrence within 6 months of platinum therapy": an adequate definition of "platinum-refractory" ovarian cancer?M Markman
Cleveland Clinic Journal of Medicine|May 23, 1998
The high cost of terminal care: balancing conflicting goalsM Markman
Seminars in Oncology|August 1, 1989
Intraperitoneal cisplatin chemotherapy in the management of ovarian carcinomaM Markman
Cancer Investigation|January 1, 1987
Clinical cancer research, DNR orders, and medical economics: a complex interrelationshipM Markman
The American Journal of the Medical Sciences|March 1, 1986
Cytotoxic intracavitary chemotherapyM Markman
Journal of Cancer Research and Clinical Oncology|January 1, 1995
Thirty-first annual meeting of the American Society of Clinical Oncology. Los Angeles, California, 20-23 May 1995M Markman
Journal of Cancer Research and Clinical Oncology|January 1, 1993
The role of platinum dose intensity in the management of ovarian cancerM Markman
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Salvage intraperitoneal chemotherapy for ovarian cancer: a possible role for mitoxantrone?M Markman
Journal of Cancer Research and Clinical Oncology|January 1, 1994
Pharmaceutical advertising and the cost of medical careM Markman
Pageof 55